InvestorsHub Logo
Followers 43
Posts 5405
Boards Moderated 0
Alias Born 03/05/2010

Re: homeslice10 post# 86946

Saturday, 08/01/2015 10:58:31 AM

Saturday, August 01, 2015 10:58:31 AM

Post# of 92948
It's been mentioned before, maybe Japan's patients need help with OCATA technology. Here is some quotes from the web about the subject.

"Ocata Competitor's AMD ips stem cell trial halted due to cancer scare"


https://www.newscientist.com/article...ure-blindness/

"As I said on another thread Japan should immediately partner with Ocata and bring in the real experts!"

BF


"the good Dr. robert is getting marketing savvy...love his quote.."

“I think it’s an easily fixable problem if they go this route,” says Robert Lanza, chief scientist at Advanced Cell Technology/OCAT in Marlborough, Massachusetts, a company that is also developing stem-cell therapies for age-related blindness"

"This sounds horrible, but the failure of these trials will ultimately help Ocata a lot. One by one, the inferior and not-ready-for-prime time stem cell treatments are falling. And since this is the treatment I would need... well, I think I have the cred to say it!!"

"Well the cell source used in the Japanese trials used ips cell derived using viral vectors to alter the cell back to its embryonic like state and the ips cells Ocata is using uses mRNA to alter it which Lanza has always said was the safe way to derive these cells. Maybe your response was retorical and you knew this already but if there's anyone that didn't know the difference between Ocatas technique and Japan's, there it is."

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.